Autologous Bone Marrow Mesenchymal Stem Cells Transplantation Via Hepatic Artery in Patients With Liver Cirrhosis

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00976287

Enrollment

Registered

2009-09-14

Start date

2008-01-31

Completion date

2010-06-30

Last updated

2009-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Cirrhosis

Keywords

Stem cells, Liver cirrhosis, Radiology, Interventional, Transplantation

Brief summary

The purpose of this study is to investigate the efficacy of autologous bone marrow mesenchymal stem cells (MSCs) transplantation via hepatic artery in the treatment of liver cirrhosis. Liver function was monitored by serum examination. The levels of serum alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT) and albumin (ALB) were examined at pre-transplantation, and 3 days to 2 years post-transplantation. Child-Pugh scores and clinical symptoms were also observed simultaneously.

Detailed description

Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.

Interventions

PROCEDUREHepatic artery infusion

PROCEDUREConserved Therapy

Conserved Therapy

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Age 18-70 years. * Imaging evidences of liver cirrhosis. * Child-Plough score of 10 or more.

Exclusion criteria

* Liver tumor on ultrasonography, CT or MRI examination. * Problems in organs other than the liver(e.g.the heart or lungs). * History of moderate to severe hepatic encephalopathy or variceal bleeding. * Imaging evidences of vascular thromboses. * Coma.

Design outcomes

Primary

Measure	Time frame
The levels of serum alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT), albumin (ALB)	pre-transplantation, and 3 days to 2 years post-transplantation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026